Vascular Biology |
From the Wallenberg Laboratory, Sahlgren's University Hospital, Göteborg, S-41345, Sweden (U.L., E.H.-C., G.O., P.S., G.C., O.W.); and the Astra Hässle AB, Preclinical Research Laboratories, Mölndal, S-431 83, Sweden (G.C.).
Correspondence to Germán Camejo, Astra Hässle AB, Preclinical Research Laboratories, Mölndal, S-431 83, Sweden. E-mail german.camejo{at}hassle.se.astra.com
AbstractLp(a) interference with
fibrinolysis could contribute to atherothrombosis.
Additionally, accumulation of Lp(a) and LDLs, could lead to
cholesterol deposition and foam cell formation in
atherogenesis. The interactions between Lp(a) and LDL could cause their
entrapment in the extracellular matrix of lesions. We found that
association of Lp(a) with matrix secreted by cultured human
arterial smooth muscle cells increased 2 to 3 times the
subsequent specific binding of radioactive LDL. Chondroitin sulfate
proteoglycans seem responsible for formation of the specific
matrix-Lp(a) and matrix-LDL aggregates. The proteoglycans appeared also
to participate in a cooperative increase of radioactive LDL binding to
matrix pretreated with Lp(a). In the matrix preincubated with LDL,
50% of the additional lipoprotein was bound by ionic interactions.
In the matrix preincubated with Lp(a), 20% of the additional LDL was
held by ionic bonds, and the rest was held by strong nonionic
associations. Binding analysis in
physiological solutions confirmed that
chondroitin sulfate-rich proteoglycans from the smooth muscle
cell matrix have a high affinity for Lp(a) and LDL. The results provide
an explanation to the observed localization of Lp(a) and LDL in the
extracellular matrix of arterial lesions and suggest a
mechanism for their cooperative accumulation there.
Key Words: lipoprotein(a) LDL smooth muscle cells extracellular matrix
This article has been cited by other articles:
![]() |
Y. Nakashima, T. N. Wight, and K. Sueishi Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans Cardiovasc Res, July 1, 2008; 79(1): 14 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Tabas, K. J. Williams, and J. Boren Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications Circulation, October 16, 2007; 116(16): 1832 - 1844. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Khalil, W. D. Wagner, and I. J. Goldberg Molecular Interactions Leading to Lipoprotein Retention and the Initiation of Atherosclerosis Arterioscler Thromb Vasc Biol, December 1, 2004; 24(12): 2211 - 2218. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Stacey, G.-W. Chang, J. Q. Davies, M. J. Kwakkenbos, R. D. Sanderson, J. Hamann, S. Gordon, and H.-H. Lin The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans Blood, October 15, 2003; 102(8): 2916 - 2924. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Vaughan, A. M. Gotto Jr., and C. T. Basson The evolving role of statins in the management of atherosclerosis J. Am. Coll. Cardiol., January 1, 2000; 35(1): 1 - 10. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |